Cargando…
Gametocyte clearance in children, from western Kenya, with uncomplicated Plasmodium falciparum malaria after artemether–lumefantrine or dihydroartemisinin–piperaquine treatment
BACKGROUND: The efficacy and safety of artemether–lumefantrine (AL) and dihydroartemisinin–piperaquine (DP) against asexual parasites population has been documented. However, the effect of these anti-malarials on sexual parasites is still less clear. Gametocyte clearance following treatment is essen...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891957/ https://www.ncbi.nlm.nih.gov/pubmed/31801562 http://dx.doi.org/10.1186/s12936-019-3032-3 |
_version_ | 1783475932592340992 |
---|---|
author | Omondi, Protus Burugu, Marion Matoke-Muhia, Damaris Too, Edwin Nambati, Eva A. Chege, William Musyoka, Kelvin B. Thiongo, Kelvin Otinga, Maureen Muregi, Francis Kimani, Francis |
author_facet | Omondi, Protus Burugu, Marion Matoke-Muhia, Damaris Too, Edwin Nambati, Eva A. Chege, William Musyoka, Kelvin B. Thiongo, Kelvin Otinga, Maureen Muregi, Francis Kimani, Francis |
author_sort | Omondi, Protus |
collection | PubMed |
description | BACKGROUND: The efficacy and safety of artemether–lumefantrine (AL) and dihydroartemisinin–piperaquine (DP) against asexual parasites population has been documented. However, the effect of these anti-malarials on sexual parasites is still less clear. Gametocyte clearance following treatment is essential for malaria control and elimination efforts; therefore, the study sought to determine trends in gametocyte clearance after AL or DP treatment in children from a malaria-endemic site in Kenya. METHODS: Children aged between 0.5 and 12 years from Busia, western Kenya with uncomplicated Plasmodium falciparum malaria were assigned randomly to AL or DP treatment. A total of 334 children were enrolled, and dried blood spot samples were collected for up to 6 weeks after treatment during the peak malaria transmission season in 2016 and preserved. Plasmodium falciparum gametocytes were detected by qRT-PCR and gametocyte prevalence, density and mean duration of gametocyte carriage were determined. RESULTS: At baseline, all the 334 children had positive asexual parasites by microscopy, 12% (40/334) had detectable gametocyte by microscopy, and 83.7% (253/302) children had gametocytes by RT-qPCR. Gametocyte prevalence by RT-qPCR decreased from 85.1% (126/148) at day 0 to 7.04% (5/71) at day 42 in AL group and from 82.4% (127/154) at day 0 to 14.5% (11/74) at day 42 in DP group. The average duration of gametocyte carriage as estimated by qRT-PCR was slightly shorter in the AL group (4.5 days) than in the DP group (5.1 days) but not significantly different (p = 0.301). CONCLUSION: The study identifies no significant difference between AL and DP in gametocyte clearance. Gametocytes persisted up to 42 days post treatment in minority of individuals in both treatment arms. A gametocytocidal drug, in combination with artemisinin-based combination therapy, will be useful in blocking malaria transmission more efficiently. |
format | Online Article Text |
id | pubmed-6891957 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68919572019-12-11 Gametocyte clearance in children, from western Kenya, with uncomplicated Plasmodium falciparum malaria after artemether–lumefantrine or dihydroartemisinin–piperaquine treatment Omondi, Protus Burugu, Marion Matoke-Muhia, Damaris Too, Edwin Nambati, Eva A. Chege, William Musyoka, Kelvin B. Thiongo, Kelvin Otinga, Maureen Muregi, Francis Kimani, Francis Malar J Research BACKGROUND: The efficacy and safety of artemether–lumefantrine (AL) and dihydroartemisinin–piperaquine (DP) against asexual parasites population has been documented. However, the effect of these anti-malarials on sexual parasites is still less clear. Gametocyte clearance following treatment is essential for malaria control and elimination efforts; therefore, the study sought to determine trends in gametocyte clearance after AL or DP treatment in children from a malaria-endemic site in Kenya. METHODS: Children aged between 0.5 and 12 years from Busia, western Kenya with uncomplicated Plasmodium falciparum malaria were assigned randomly to AL or DP treatment. A total of 334 children were enrolled, and dried blood spot samples were collected for up to 6 weeks after treatment during the peak malaria transmission season in 2016 and preserved. Plasmodium falciparum gametocytes were detected by qRT-PCR and gametocyte prevalence, density and mean duration of gametocyte carriage were determined. RESULTS: At baseline, all the 334 children had positive asexual parasites by microscopy, 12% (40/334) had detectable gametocyte by microscopy, and 83.7% (253/302) children had gametocytes by RT-qPCR. Gametocyte prevalence by RT-qPCR decreased from 85.1% (126/148) at day 0 to 7.04% (5/71) at day 42 in AL group and from 82.4% (127/154) at day 0 to 14.5% (11/74) at day 42 in DP group. The average duration of gametocyte carriage as estimated by qRT-PCR was slightly shorter in the AL group (4.5 days) than in the DP group (5.1 days) but not significantly different (p = 0.301). CONCLUSION: The study identifies no significant difference between AL and DP in gametocyte clearance. Gametocytes persisted up to 42 days post treatment in minority of individuals in both treatment arms. A gametocytocidal drug, in combination with artemisinin-based combination therapy, will be useful in blocking malaria transmission more efficiently. BioMed Central 2019-12-04 /pmc/articles/PMC6891957/ /pubmed/31801562 http://dx.doi.org/10.1186/s12936-019-3032-3 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Omondi, Protus Burugu, Marion Matoke-Muhia, Damaris Too, Edwin Nambati, Eva A. Chege, William Musyoka, Kelvin B. Thiongo, Kelvin Otinga, Maureen Muregi, Francis Kimani, Francis Gametocyte clearance in children, from western Kenya, with uncomplicated Plasmodium falciparum malaria after artemether–lumefantrine or dihydroartemisinin–piperaquine treatment |
title | Gametocyte clearance in children, from western Kenya, with uncomplicated Plasmodium falciparum malaria after artemether–lumefantrine or dihydroartemisinin–piperaquine treatment |
title_full | Gametocyte clearance in children, from western Kenya, with uncomplicated Plasmodium falciparum malaria after artemether–lumefantrine or dihydroartemisinin–piperaquine treatment |
title_fullStr | Gametocyte clearance in children, from western Kenya, with uncomplicated Plasmodium falciparum malaria after artemether–lumefantrine or dihydroartemisinin–piperaquine treatment |
title_full_unstemmed | Gametocyte clearance in children, from western Kenya, with uncomplicated Plasmodium falciparum malaria after artemether–lumefantrine or dihydroartemisinin–piperaquine treatment |
title_short | Gametocyte clearance in children, from western Kenya, with uncomplicated Plasmodium falciparum malaria after artemether–lumefantrine or dihydroartemisinin–piperaquine treatment |
title_sort | gametocyte clearance in children, from western kenya, with uncomplicated plasmodium falciparum malaria after artemether–lumefantrine or dihydroartemisinin–piperaquine treatment |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891957/ https://www.ncbi.nlm.nih.gov/pubmed/31801562 http://dx.doi.org/10.1186/s12936-019-3032-3 |
work_keys_str_mv | AT omondiprotus gametocyteclearanceinchildrenfromwesternkenyawithuncomplicatedplasmodiumfalciparummalariaafterartemetherlumefantrineordihydroartemisininpiperaquinetreatment AT burugumarion gametocyteclearanceinchildrenfromwesternkenyawithuncomplicatedplasmodiumfalciparummalariaafterartemetherlumefantrineordihydroartemisininpiperaquinetreatment AT matokemuhiadamaris gametocyteclearanceinchildrenfromwesternkenyawithuncomplicatedplasmodiumfalciparummalariaafterartemetherlumefantrineordihydroartemisininpiperaquinetreatment AT tooedwin gametocyteclearanceinchildrenfromwesternkenyawithuncomplicatedplasmodiumfalciparummalariaafterartemetherlumefantrineordihydroartemisininpiperaquinetreatment AT nambatievaa gametocyteclearanceinchildrenfromwesternkenyawithuncomplicatedplasmodiumfalciparummalariaafterartemetherlumefantrineordihydroartemisininpiperaquinetreatment AT chegewilliam gametocyteclearanceinchildrenfromwesternkenyawithuncomplicatedplasmodiumfalciparummalariaafterartemetherlumefantrineordihydroartemisininpiperaquinetreatment AT musyokakelvinb gametocyteclearanceinchildrenfromwesternkenyawithuncomplicatedplasmodiumfalciparummalariaafterartemetherlumefantrineordihydroartemisininpiperaquinetreatment AT thiongokelvin gametocyteclearanceinchildrenfromwesternkenyawithuncomplicatedplasmodiumfalciparummalariaafterartemetherlumefantrineordihydroartemisininpiperaquinetreatment AT otingamaureen gametocyteclearanceinchildrenfromwesternkenyawithuncomplicatedplasmodiumfalciparummalariaafterartemetherlumefantrineordihydroartemisininpiperaquinetreatment AT muregifrancis gametocyteclearanceinchildrenfromwesternkenyawithuncomplicatedplasmodiumfalciparummalariaafterartemetherlumefantrineordihydroartemisininpiperaquinetreatment AT kimanifrancis gametocyteclearanceinchildrenfromwesternkenyawithuncomplicatedplasmodiumfalciparummalariaafterartemetherlumefantrineordihydroartemisininpiperaquinetreatment |